Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoring

Clinical Transplantation

Volumn 28, Issue 2, 2014, Pages 243-251

  Holt, David W ^a   Mandelbrot, Didier A ^b   Tortorici, Michael A ^c   Korth Bradley, Joan M ^c   Sierka, Debra ^c   Levy, Daniel I ^c   See Tai, Sandi ^c   Horowitz, Gary L ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

Assay calibration; Immunoassay; Liquid chromatography; Sirolimus; Therapeutic drug monitoring

Indexed keywords

ASSAY CALIBRATION; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; SIROLIMUS; THERAPEUTIC DRUG MONITORING;

CHROMATOGRAPHY, LIQUID; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOASSAY; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 84895077292     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12305     Document Type: Article

References (31)

1. Wyeth Pharmaceuticals Inc. Rapamune [Package Insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2012.
2. Rapamune Summary of Product Characteristics. 2011; European Medicine Agency. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000273/WC500046437.pdf. Accessed: May 9, 2013.
3. Kahan BD, Napoli KL, Kelly PA et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000: 14: 97.
4. Wu MJ, Shu KH, Lian JD et al. Impact of variability of sirolimus trough level on chronic allograft nephropathy. Transplant Proc 2008: 40: 2202.
5. Cattaneo D, Merlini S, Pellegrino M et al. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004: 4: 1345.
6. MacDonald A, Scarola J, Burke JT et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000: 22(Suppl B): B101.
7. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001: 40: 573.
8. Holt DW, Denny K, Lee TD et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 2003: 35: 157S.
9. Holt DW, Lee T, Johnston A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin Ther 2000: 22(Suppl B): B38.
10. Napoli KL. A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection. Clin Ther 2000: 22(Suppl B): B14.
11. Holt DW, Lee T, Jones K et al. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 2000: 46: 1179.
12. Abbott Laboratories. IMx Sirolimus Assay [Package Insert]. Abbott Park, IL: Abbott Laboratories, 2006.
13. Abbott Laboratories. Architect Sirolimus Assay [Package Insert]. Abbott Park, IL: Abbott Laboratories, 2012.
14. Wilson D, Johnston F, Holt D et al. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus. Clin Biochem 2006: 39: 378.
15. Zochowska D, Bartlomiejczyk I, Kaminska A et al. High-performance liquid chromatography versus immunoassay for the measurement of sirolimus: comparison of two methods. Transplant Proc 2006: 38: 78.
16. Holt DW, Moreton M, Laamanen K et al. A microparticle enzyme immunoassay to measure sirolimus. Transplant Proc 2005: 37: 182.
17. Morris RG, Salm P, Taylor PJ et al. Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients. Ther Drug Monit 2006: 28: 164.
18. Johnson-Davis KL, De S, Jimenez E et al. Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method. Ther Drug Monit 2011: 33: 453.
19. Camardo J. Dear Health Care Provider: Important Drug Information [Letter]. Silver Spring, MD: Food and Drug Administration, 12-17-2009. Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM197064.pdf. Accessed May 9, 2013.
20. Wilson DH, Sepe D, Barnes G et al. Inter-laboratory differences in sirolimus results from six sirolimus testing centers using HPLC tandem mass spectrometry (LC/MS/MS). Clin Chim Acta 2005: 355: 211.
21. Schmid RW, Lotz J, Schweigert R et al. Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer. Clin Biochem 2009: 42: 1543.
22. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 2005: 44: 769.
23. Holt DW, McKeown DA, Lee TD et al. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplant Proc 2004: 36: 3223.
24. Scholer A, Von RR, Faffa G et al. Evaluation of a microparticle enzyme immunoassay for the measurement of sirolimus in whole blood (Abbott IMx sirolimus). Clin Lab 2006: 52: 325.
25. ® MEIA method. Clin Chem Lab Med 2010: 48: 1523.
26. Kahn SE, Vazquez D, Meyer P et al. Analytical evaluation of the Abbott Architect sirolimus assay [abstract]. Presented at the IFCC-WorldLab 2008, 20th International Congress of Clinical Chemistry and Laboratory Medicine, Fortaleza, Brazil; September 28-October 2, 2008.
27. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007: 357: 2562.
28. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001: 71: 271.
29. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194.
30. Ekberg H, Mamelok RD, Pearson TC et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation 2009: 87: 1360.
31. Miller WG, Jones GR, Horowitz GL et al. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem 2011: 57: 1670.